GSK received an FDA approval for zidesamtinib, branded Jideytro, in ROS1-positive metastatic non-small-cell lung cancer shortly after closing its $10.6 billion Nuvalent acquisition. The accelerated timing turned GSK’s largest oncology bet into near-term commercial momentum, with the approval coming well ahead of an expected Sept. decision date. The label supports use in adults with locally advanced or metastatic ROS1-positive NSCLC after prior ROS1 kinase inhibitor therapy. The coverage links the early approval to breakthrough therapy and orphan drug designations that can shorten timelines for qualifying oncology medicines. The Nuvalent purchase also included neladalkib, which remains under FDA review, meaning GSK’s oncology monetization timeline could extend further if additional regulatory outcomes follow. For biotech investors, the approval highlights how large dealmaking is increasingly judged on rapid execution and regulatory catalysts rather than only long-term pipeline potential.